Program
Aspirin
Also written as “dabigatran with ASA”, “ASA” and “Acetylsalicylic acid (Aspirin, BAY1019036)”.
Its studies are mostly in Coronary Artery Disease · Cardiovascular Diseases · Common Cold · Thrombosis · Peptic Ulcer, led by 28 companies.
Drug pageAspirin: every studyMany companies study it; this page follows only the 70 they lead. All 675 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayerits history only | 211 open or running | phase 4since Dec 15, 2009 | Jul 12, 2007 | Mar 10, 2027phase 1 · NCT07652723 |
| Boehringer Ingelheimits history only | 60 open or running | phase 4since Aug 10, 2005 | Aug 10, 2005 | none ahead |
| Bristol-Myers Squibbits history only | 50 open or running | phase 1since Jul 8, 2009 | Jul 8, 2009 | none ahead |
| Abbottits history only | 30 open or running | phase 3since Feb 21, 2008 | Feb 21, 2008 | none ahead |
| Boston Scientificits history only | 30 open or running | phase 4since May 1, 2012 | Dec 21, 2011 | none ahead |
| Johnson & Johnsonits history only | 30 open or running | phase 4since Dec 2, 2005 | Dec 2, 2005 | none ahead |
| Aralez Pharmaceuticalsits history only | 20 open or running | phase 1since Feb 27, 2007 | Feb 27, 2007 | none ahead |
| Astellas Pharmaits history only | 20 open or running | phase 4since May 26, 2016 | Aug 1, 2011 | none ahead |
| Biogenits history only | 20 open or running | phase 4since Mar 14, 2014 | Jan 20, 2011 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 20 open or running | phase 1since Dec 20, 2010 | Dec 20, 2010 | none ahead |
| GlaxoSmithKlineits history only | 20 open or running | phase 1since May 2, 2013 | May 2, 2013 | none ahead |
| Merckits history only | 20 open or running | phase 1since Nov 10, 2009 | Nov 10, 2009 | none ahead |
| PLx Pharmaits history only | 20 open or running | phase 2since Mar 10, 2009 | Mar 10, 2009 | none ahead |
| Azidus Brasilits history only | 10 open or running | phase 3since Nov 12, 2009 | Nov 12, 2009 | none ahead |
| celonova-biosciences-incits history only | 10 open or running | no phasesince Aug 19, 2014 | Aug 19, 2014 | none ahead |
| Cordisits history only | 10 open or running | phase 4since Aug 6, 2009 | Aug 6, 2009 | none ahead |
| Egymedicalpediaits history only | 11 open or running | no phasesince Feb 7, 2024 | Feb 7, 2024 | none ahead |
| fertility-center-of-las-vegasits history only | 11 open or running | phase 4since Nov 10, 2023 | Nov 10, 2023 | none ahead |
| GC Biopharmaits history only | 10 open or running | phase 4since May 16, 2019 | May 16, 2019 | none ahead |
| Hamad Medicalits history only | 10 open or running | phase 4since Mar 23, 2020 | Mar 23, 2020 | none ahead |
| Laboratorios Silanes S.A. de C.V.its history only | 10 open or running | phase 1since Feb 24, 2026 | Feb 24, 2026 | none ahead |
| new-haven-pharmaceuticals-incits history only | 10 open or running | phase 1since Feb 11, 2015 | Feb 11, 2015 | none ahead |
| Novartisits history only | 10 open or running | phase 4since Nov 23, 2010 | Nov 23, 2010 | none ahead |
| Otsukaits history only | 10 open or running | phase 1since Sep 15, 2015 | Sep 15, 2015 | none ahead |
| Regeneron Pharmaceuticalsits history only | 10 open or running | no phasesince Sep 15, 2022 | Sep 15, 2022 | none ahead |
| rhoshan-pharmaceuticals-incits history only | 10 open or running | phase 1since Dec 18, 2025 | Dec 18, 2025 | none ahead |
| vectura-incits history only | 10 open or running | phase 1since Nov 1, 2022 | Nov 1, 2022 | none ahead |
| vita-green-health-products-co-ltdits history only | 10 open or running | phase 1since Mar 4, 2021 | Mar 4, 2021 | none ahead |
Also a collaborator on its studies: Cardialysis, Terumo and ClinLogix.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Aug 6, 2009.
- Oct 4, 2018Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT03698513 · 113 enrolled · United States
- May 16, 2019GC Biopharma’s first study: phase 4 study in Mucocutaneous Lymph Node SyndromeNew to GC BiopharmaGC Biopharma · NCT04003844 · 45 enrolled · Korea, Republic of
- Jul 2, 2019Phase 1 study in BioequivalencePLx Pharma · NCT04008979 · 32 enrolled
- Aug 21, 2019No phase study in Heart FailureAbbott · NCT04069156 · 628 enrolled · United States, Australia, Austria and more
- Mar 23, 2020Hamad Medical’s first study: phase 4 study in Ischemic StrokeNew to Hamad MedicalHamad Medical · NCT04330872 · 42 enrolled · Qatar
- Mar 4, 2021vita-green-health-products-co-ltd’s first study: phase 1 study in Cardiovascular DiseasesNew to vita-green-health-products-co-ltdvita-green-health-products-co-ltd · NCT04792723 · 24 enrolled
- Sep 15, 2022Regeneron Pharmaceuticals’ first study: no phase study in DiseaseNew to Regeneron PharmaceuticalsRegeneron Pharmaceuticals · NCT05546957 · 60 enrolled · United Kingdom
- Nov 1, 2022vectura-inc’s first study: phase 1 study in Respiratory AspirationNew to vectura-incvectura-inc · NCT05625334 · 86 enrolled · United States
- Nov 10, 2023fertility-center-of-las-vegas’ first study: phase 4 study in Infertility, FemaleNew to fertility-center-of-las-vegasfertility-center-of-las-vegas · NCT06133803 · 130 planned · United States
- Feb 7, 2024Egymedicalpedia’s first study: no phase study in Pre-EclampsiaNew to EgymedicalpediaEgymedicalpedia · NCT06261203 · 250 planned · Egypt
- Oct 22, 2024Phase 1 study in BioequivalenceBayer · NCT06655194 · 38 enrolled · Mexico
- Dec 18, 2025rhoshan-pharmaceuticals-inc’s first study: phase 1 study in HealthyNew to rhoshan-pharmaceuticals-incrhoshan-pharmaceuticals-inc · NCT07323680 · 40 enrolled · Czechia
- Feb 24, 2026Laboratorios Silanes S.A. de C.V.’s first study: phase 1 study in HealthyNew to Laboratorios Silanes S.A. de C.V.Laboratorios Silanes S.A. de C.V. · NCT07444164 · 24 enrolled · Mexico
- Jun 8, 2026Phase 1 study in Drug-drug InteractionBayer · NCT07652723 · 16 planned · United States
Ahead
- Mar 10, 2027Primary completion: phase 1 study in Drug-drug InteractionBayer · NCT07652723
TargetBeta
“Cyclooxygenase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Acetaminophenrule | Johnson & Johnson | phase 4 | 136 |
| Ibuprofenrule | Pfizer | phase 4 | 113 |
| dexketoprofenrule | Menarini Group | phase 4 | 8 |
| Sulfasalazinerule | Bristol-Myers Squibb | phase 4 | 7 |
| dexibuprofenrule | aponia-laboratories-inc | phase 4 | 6 |
| Benzydaminerule | Angelini Pharma | phase 4 | 4 |
| Dipyronerule | Hypera Pharma | phase 4 | 4 |
| Piroxicamrule | Taisho Pharmaceutical | phase 4 | 4 |
| Flurbiprofenrule | GlaxoSmithKline | phase 3 | 12 |
Studies
The newest 60 of 70 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07652723Drug-drug Interaction · United States | 1 | Recruiting | Bayer | Mar 10, 2027 | 16 |
| NCT07444164Healthy · Mexico | 1 | Completed | Laboratorios Silanes S.A. de C.V. | Jan 23, 2025 | 24 |
| NCT07323680Healthy · Czechia | 1 | Completed | rhoshan-pharmaceuticals-inc | Jul 7, 2025 | 40 |
| NCT06655194Bioequivalence · Mexico | 1 | Completed | Bayer | Apr 6, 2025 | 38 |
| NCT06261203Pre-Eclampsia · Egypt | – | Recruiting | Egymedicalpedia | Jul 1, 2025 | 250 |
| NCT06133803Infertility, Female · United States | 4 | Recruiting | fertility-center-of-las-vegas | Dec 15, 2024 | 130 |
| NCT05625334Respiratory Aspiration · United States | 1 | Completed | vectura-inc | Mar 9, 2023 | 86 |
| NCT05546957Disease · United Kingdom | – | Completed | Regeneron Pharmaceuticals | Apr 6, 2023 | 60 |
| NCT04792723Cardiovascular Diseases | 1 | UNKNOWN | vita-green-health-products-co-ltd | Jul 1, 2021 | 24 |
| NCT04330872Ischemic Stroke · Qatar | 4 | Completed | Hamad Medical | Jan 4, 2020 | 42 |
| NCT04069156Heart Failure · United States, Australia, Austria and more | – | Completed | Abbott | Aug 10, 2023 | 628 |
| NCT04008979Bioequivalence | 1 | Completed | PLx Pharma | Jun 10, 2008 | 32 |
| NCT04003844Mucocutaneous Lymph Node Syndrome · Korea, Republic of | 4 | Completed | GC Biopharma | Nov 22, 2019 | 45 |
| NCT03698513Healthy Volunteers · United States | 1 | Completed | Bristol-Myers Squibb | Feb 19, 2019 | 113 |
| NCT03225352Moderate Pain · United Kingdom | 1 | Completed | Bayer | Oct 7, 2017 | 12 |
| NCT03197779Thrombosis · United States | 1 | Completed | Bristol-Myers Squibb | Feb 2, 2016 | 691 |
| NCT03056703Pain · United States | 1 | Completed | Bayer | Mar 2014 | 38 |
| NCT02846532Thrombosis · United States, Argentina, Belgium and more | 3 | Completed | Johnson & Johnson | Jul 16, 2020 | 112 |
| NCT02786979Diabetes Mellitus, Type 2 · China | 4 | Terminated | Astellas Pharma | Jan 2013 | 190 |
| NCT02554721Healthy · Germany | 1 | Completed | Otsuka | Mar 30, 2018 | 77 |
| NCT02439190Thrombosis · United Kingdom | 1 | Completed | Bristol-Myers Squibb | Mar 2016 | 42 |
| NCT02394093Pharmacology, Clinical · United States | 1 | Completed | Bayer | Mar 2015 | 30 |
| NCT02370680Cardiovascular Diseases · United States | 1 | Completed | new-haven-pharmaceuticals-inc | Jul 2015 | 41 |
| NCT02341638Thrombosis · United States | 1 | Completed | Bristol-Myers Squibb | Sep 2015 | 148 |
| NCT02268773Healthy | 1 | Completed | Boehringer Ingelheim | May 2000 | 27 |
| NCT02262793Healthy | 1 | Completed | Boehringer Ingelheim | Jul 2004 | 24 |
| NCT02224235Angina, Stable · Finland | – | Terminated | celonova-biosciences-inc | Jun 2015 | 8 |
| NCT02183688Migraine Disorders | 3 | Completed | Boehringer Ingelheim | Jan 2003 | 1,889 |
| NCT02090413Multiple Sclerosis, Relapsing-Remitting · Ireland, United Kingdom | 4 | Completed | Biogen | Feb 2015 | 241 |
| NCT01847417Ulcer · India | 1 | Completed | GlaxoSmithKline | Jul 1, 2013 | 24 |
| NCT01847404Ulcer · India | 1 | Completed | GlaxoSmithKline | Jun 28, 2013 | 24 |
| NCT01830543Atrial Fibrillation · United States, Argentina, Australia and more | 3 | Completed | Johnson & Johnson | Jul 28, 2016 | 2,124 |
| NCT01776424Coronary Artery Disease · United States, Argentina, Australia and more | 3 | Completed | Bayer | Jul 21, 2017 | 27,395 |
| NCT01589978Coronary Artery Disease · United States | 4 | Completed | Boston Scientific | Aug 2014 | 2,681 |
| NCT01552798Headache · United States | 3 | Terminated | Bayer | Jun 4, 2012 | 9 |
| NCT01500434Coronary Artery Disease · United States, Australia, Belgium and more | 3 | Completed | Boston Scientific | Mar 2011 | 102 |
| NCT01510327Coronary Artery Disease · United States, Japan | 3 | Completed | Boston Scientific | Feb 2010 | 22 |
| NCT01496261Coronary Artery Disease · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Sep 2011 | 60 |
| NCT01424332Pharmacodynamic and Pharmacokinetic Interaction · France | 1 | Completed | Astellas Pharma | Mar 2008 | 24 |
| NCT01420094Toothache · United States | 3 | Completed | Bayer | Sep 8, 2011 | 510 |
| NCT01361399Common Cold · Russian Federation, Ukraine | 3 | Completed | Bayer | May 28, 2005 | 1,088 |
| NCT01465009Common Cold · United Kingdom | 4 | Completed | Bayer | 508 | |
| NCT01464983Headache · United Kingdom | 4 | Completed | Bayer | 1,115 | |
| NCT01464944Respiratory Tract Infections · Russian Federation, Ukraine | 4 | Completed | Bayer | 392 | |
| NCT01281111Healthy · United States | 1 | Completed | Biogen | Mar 18, 2011 | 56 |
| NCT01663038Coronary Artery Disease · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Jan 2011 | 60 |
| NCT01248468Pain · United States | 4 | Completed | Novartis | Mar 2011 | 752 |
| NCT01227629Atrial Fibrillation · United States, Denmark, Sweden | 2 | Completed | Boehringer Ingelheim | Nov 2004 | 502 |
| NCT01122602Drugs, Investigational · United States | 3 | Completed | Bayer | Jul 29, 2010 | 500 |
| NCT01117636Drugs, Investigational · United States | 3 | Completed | Bayer | Jul 7, 2010 | 514 |
| NCT01108588Healthy Volunteers | 1 | Completed | Merck | Aug 2010 | 15 |
| NCT01081353Pharmacokinetics · United States | 1 | Completed | Bayer | Mar 2010 | 26 |
| NCT01072604Pharmacokinetics · United States | 1 | Completed | Bayer | Aug 2009 | 30 |
| NCT01033526Common Cold · Italy | 4 | Completed | Bayer | 388 | |
| NCT01062360Common Cold · United States, Italy, Poland and more | 3 | Completed | Bayer | May 14, 2007 | 1,016 |
| NCT01028079Low Back Pain · Germany, United Kingdom | 3 | Completed | Bayer | 338 | |
| NCT01012349Treatment of Episodic Tension Headache · Brazil | 3 | UNKNOWN | Azidus Brasil | May 2011 | 152 |
| NCT01012219Hyperlipoproteinemia Type II | 1 | Completed | Merck | Mar 2010 | 36 |
| NCT00963443Common Cold · United Kingdom | 3 | Completed | Bayer | Mar 2012 | 833 |
| NCT00954707Coronary Artery Disease · United States | 4 | UNKNOWN | Cordis | Jan 2012 | 2,509 |
How it is read
Names in the registry
- “Aspirin”, 25 entries
- “dabigatran with ASA”, 6 entries
- “ASA”, 5 entries
- “Acetylsalicylic acid (Aspirin, BAY1019036)”, 5 entries
- “Acetylsalicylic acid (Aspirin, BAYE4465)”, 5 entries
Codes read as this program: BAY1019036.
Conditions, from the studies’ own filings
- Coronary Artery Disease, 9 studies
- Cardiovascular Diseases, 5 studies
- Common Cold, 5 studies
- Thrombosis, 4 studies
- Peptic Ulcer, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.